ExonHit Therapeutics, bioMerieux To Terminate Colon Cancer Collaboration
However, both companies will continue to collaborate in the field of prostate cancer. Loic Maurel, president of management board at ExonHit, said: “ExonHit’s technology was able to produce
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.